SLNO
Soleno Therapeutics, Inc.
$53.01
+0.00
(+0.00%)
Mkt Cap
2.76B
Volume
4,968,834
52W Range
29.43-90.3199
Sector
Healthcare
Beta
-2.22
EPS (TTM)
1.96
P/E Ratio
27.09
Revenue (TTM)
285.01M
Rev Growth (5Y)
+71.9%
EPS Growth (5Y)
N/A
AlphaVal · Fair Value
What we estimate one share is worth
$52.65
Overvalued
weak signal
0.7% above fair value
Modeled from cash flows & growth.
AlphaQuality · Grade · Gated
How strong & durable the business is
F
High-Growth Software
30.0 / 100 pillar composite (overridden)
Fast-growing software, still scaling up — graded A–F vs. similar companies.
Company Description
Soleno Therapeutics, Inc. (SLNO) operates as a clinical-stage biopharmaceutical company, specializing in the creation and market introduction of groundbreaking treatments for uncommon illnesses. The cornerstone of its therapeutic pipeline is Diazoxide Choline Controlled-Release, a once-daily oral tablet aimed at addressing Prader-Willi Syndrome, currently progressing through an active Phase III clinical evaluation. Established in 1999, the Redwood City, California-headquartered firm adopted its current name, Soleno Therapeutics, Inc., in May 2017, having previously operated as Capnia, Inc.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 190.41M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | (1.55B) | 1.45M | 387,555 | 0 |
| Net Income | 20.89M | (175.85M) | (38.99M) | (24.07M) | (30.91M) | (24.64M) | (30.77M) | (13.34M) | (15.67M) | (12.07M) | (15.91M) | (13.87M) |
| EPS | 0.41 | -4.38 | -2.36 | -2.87 | -5.81 | -3.68 | -15.78 | -9.54 | -26.18 | -58.35 | -126.58 | -819.38 |
| Free Cash Flow | 46.73M | (69.31M) | (24.94M) | (20.79M) | (27.79M) | (25.23M) | (17.40M) | (11.69M) | (9.95M) | (13.54M) | (10.61M) | (4.52M) |
| FCF / Share | 0.88 | -1.73 | -1.51 | -2.48 | -5.23 | -6.04 | -7.64 | -8.36 | -16.63 | -65.47 | -84.38 | -266.64 |
| Operating CF | 46.80M | (69.10M) | (24.94M) | (20.78M) | (27.77M) | (25.22M) | (17.38M) | (11.68M) | (9.95M) | (13.50M) | (10.30M) | (4.48M) |
| Total Assets | 563.83M | 330.97M | 180.69M | 26.50M | 35.55M | 64.98M | 38.17M | 43.15M | 39.02M | 5.56M | 8.20M | 8.40M |
| Total Debt | 2.69M | 52.83M | 403,000 | 155,000 | 457,000 | 139,000 | 305,000 | 0 | 0 | 0 | 0 | 101,529 |
| Cash & Equiv | 70.11M | 87.93M | 169.68M | 14.60M | 21.30M | 49.22M | 20.73M | 23.10M | 17.10M | 2.73M | 5.49M | 7.96M |
| Book Value | 450.12M | 245.11M | 157.51M | 10.35M | 17.79M | 45.55M | 14.95M | 30.41M | 26.53M | 3.44M | 3.22M | (10.33M) |
| Return on Equity | 0.05 | -0.72 | -0.25 | -2.33 | -1.74 | -0.54 | -2.06 | -0.44 | -0.59 | -3.51 | -4.93 | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 94.60M | 91.73M | 66.02M | 32.66M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | 31.38M | 43.36M | 26.01M | (4.71M) | (43.77M) | (55.98M) | (76.62M) | (21.85M) | (21.40M) | (11.30M) | (10.86M) | (8.47M) |
| EPS | 0.60 | 0.96 | 0.49 | -0.09 | -0.95 | -1.27 | -1.83 | -0.57 | -0.59 | -0.43 | -0.95 | -0.81 |
| Free Cash Flow | 25.94M | 48.65M | 43.63M | (12.62M) | (32.76M) | (24.00M) | (15.12M) | (17.66M) | (12.54M) | (6.31M) | (6.33M) | (5.57M) |
| FCF / Share | 0.50 | 0.91 | 0.82 | -0.25 | -0.71 | -0.55 | -0.36 | -0.46 | -0.35 | -0.24 | -0.55 | -0.53 |
| Operating CF | 25.98M | 48.70M | 43.63M | (12.61M) | (32.75M) | (23.99M) | (14.93M) | (17.65M) | (12.53M) | (6.31M) | (6.33M) | (5.57M) |
| Total Assets | 608.39M | 563.83M | 599.89M | 332.31M | 318.09M | 330.97M | 296.71M | 304.13M | 168.84M | 180.69M | 63.55M | 30.94M |
| Total Debt | 4.41M | 2.69M | 2.81M | 52.77M | 52.79M | 52.83M | 3.03M | 296,000 | 347,000 | 403,000 | 470,000 | 485,000 |
| Cash & Equiv | 133.03M | 70.11M | 246.66M | 76.50M | 81.33M | 87.93M | 48.41M | 57.02M | 42.85M | 169.68M | 52.44M | 19.37M |
| Book Value | 495.80M | 450.12M | 494.81M | 240.14M | 232.26M | 245.11M | 264.70M | 280.76M | 143.39M | 157.51M | 23.22M | 12.43M |
| Return on Equity | 0.06 | 0.10 | 0.05 | -0.02 | -0.19 | -0.23 | -0.29 | -0.08 | -0.15 | -0.07 | -0.47 | -0.68 |
SLNO News
SLNO 8-DAY DEADLINE ALERT: Hagens Berman Alerts Soleno Therapeutics (SLNO) Investors to Securities Class Action Alleging Hyperphagia Drug Launch Disruptions - Hagens Berman
SOLENO DEADLINE TODAY: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Soleno Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SLNO
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Soleno Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – SLNO
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: XOMA Royalty Corporation (Nasdaq – XOMA), Organon & Co. (NYSE – OGN), RE/MAX Holdings, Inc. (NYSE – RMAX), Soleno Therapeutics, Inc. (Nasdaq – SLNO)
SLNO DEADLINE ALERT: Hagens Berman Alerts Soleno Therapeutics (SLNO) Investors to Today's Lead Plaintiff Deadline in Securities Class Action
Halper Sadeh LLC is Investigating Whether SLNO, APLS, HLX are Obtaining Fair Deals for their Shareholders
Bronstein, Gewirtz & Grossman LLC Urges Soleno Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
DEADLINE ALERT for EOSE, SLNO, and NKTR: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
Portnoy Law Firm Announces Class Action on Behalf of Soleno Therapeutics, Inc. Investors
SLNO Shareholder Alert: Soleno Therapeutics, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact The Gross Law Firm